177 related articles for article (PubMed ID: 35641852)
21. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
22. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
23. [Clinical characteristics of patients with Breast and / or Ovarian Cancer with mutations in the BRCA1 and BRCA2 genes in Córdoba, Argentina].
Martin CA; Suárez Villasmil L; Sembaj A; Gomez Balangione F; Zunino S; Montes CDC; Borello A; Del Castillo A; Zeballos M; Rossi NT
Rev Fac Cien Med Univ Nac Cordoba; 2022 Sep; 79(3):228-234. PubMed ID: 36149077
[TBL] [Abstract][Full Text] [Related]
24. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
25. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.
Moran A; O'Hara C; Khan S; Shack L; Woodward E; Maher ER; Lalloo F; Evans DG
Fam Cancer; 2012 Jun; 11(2):235-42. PubMed ID: 22187320
[TBL] [Abstract][Full Text] [Related]
26. Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report.
Liu Y; Zhu J; Wei X; Yang D; Li S; Qian X; Li L
J Ovarian Res; 2022 Dec; 15(1):127. PubMed ID: 36463302
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract][Full Text] [Related]
28. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
[TBL] [Abstract][Full Text] [Related]
30. The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study.
Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
World J Surg Oncol; 2021 Feb; 19(1):36. PubMed ID: 33531027
[TBL] [Abstract][Full Text] [Related]
31. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
32. Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
Negura L; Uhrhammer N; Negura A; Artenie V; Carasevici E; Bignon YJ
Fam Cancer; 2010 Dec; 9(4):519-23. PubMed ID: 20567915
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
34. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
35. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
36. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
[TBL] [Abstract][Full Text] [Related]
37. Five Italian Families with Two Mutations in
Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Dello Ioio C; Cioffi M; Molinari AM
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33287145
[TBL] [Abstract][Full Text] [Related]
38. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
39. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.
Tonin PN; Maugard CM; Perret C; Mes-Masson AM; Provencher DM
Fam Cancer; 2007; 6(4):491-7. PubMed ID: 17636423
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan.
Nakamura S; Takahashi M; Tozaki M; Nakayama T; Nomizu T; Miki Y; Murakami Y; Aoki D; Iwase T; Nishimura S; Yamauchi H; Ohsumi S; Baba S; Shimizu T
Breast Cancer; 2015 Sep; 22(5):462-8. PubMed ID: 24249303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]